Mission Statement, Vision, & Core Values (2024) of Vaxart, Inc. (VXRT)

Mission Statement, Vision, & Core Values (2024) of Vaxart, Inc. (VXRT)

US | Healthcare | Biotechnology | NASDAQ

Vaxart, Inc. (VXRT) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Vaxart, Inc. (VXRT)

General Summary of Vaxart, Inc. (VXRT)

Vaxart, Inc. is a biotechnology company headquartered in South San Francisco, California. The company specializes in developing oral vaccine technologies and tablet-based vaccine platforms.

Company Detail Specific Information
Founded 2004
Stock Exchange NASDAQ
Ticker Symbol VXRT
Primary Focus Oral vaccine development

Company Products and Services

  • Oral vaccine platform technology
  • COVID-19 vaccine candidates
  • Influenza vaccine research
  • Norovirus vaccine development

Financial Performance

Financial Metric 2023 Data
Total Revenue $11.4 million
Net Loss $74.3 million
Research & Development Expenses $45.2 million
Cash and Cash Equivalents $79.6 million

Industry Leadership

Vaxart is recognized for its innovative oral vaccine technology platform, positioning itself as a potential disruptor in vaccine development. The company's unique approach to vaccine delivery through oral tablets differentiates it from traditional injectable vaccine manufacturers.

Key Competitive Advantage Description
Oral Vaccine Platform Tablet-based vaccine delivery mechanism
Patent Portfolio Multiple vaccine technology patents
Research Focus Infectious disease vaccine development



Mission Statement of Vaxart, Inc. (VXRT)

Mission Statement of Vaxart, Inc. (VXRT)

Vaxart, Inc. focuses on developing oral vaccine technologies and innovative pharmaceutical solutions targeting infectious diseases and viral challenges.

Core Components of Mission Statement

Component Specific Details
Technology Focus Oral vaccine platform development
Target Market Infectious disease interventions
Innovation Strategy Advanced pharmaceutical research

Key Strategic Objectives

  • Develop oral tablet vaccine technologies
  • Create alternative vaccine delivery mechanisms
  • Address global infectious disease challenges

Research and Development Investment

Vaxart invested $34.7 million in R&D expenses for fiscal year 2022, representing a significant commitment to technological advancement.

Technological Platform Capabilities

Platform Attribute Specification
Vaccine Delivery Oral tablet format
Development Stage Clinical trial progression
Target Pathogens Multiple viral strains

Financial Performance Metrics

Vaxart reported total revenue of $2.4 million for 2022, with ongoing research investments supporting mission-critical objectives.




Vision Statement of Vaxart, Inc. (VXRT)

Vision Statement Components of Vaxart, Inc. (VXRT) in 2024

Innovative Vaccine Technology Leadership

Vaxart's vision focuses on developing oral vaccine platforms with specific technological objectives:

  • Oral tablet vaccine technology advancement
  • Targeting global infectious disease prevention
  • Developing mucosal immune response platforms
Technology Focus Area Current Development Stage Research Investment
Oral Vaccine Platform Clinical Stage $24.7 million R&D expenditure (2023)
Infectious Disease Targets Multiple Preclinical/Clinical Trials 5 active vaccine development programs
Global Healthcare Impact Strategy

Vaxart aims to transform vaccine delivery through innovative oral technologies.

  • Reducing vaccine administration complexities
  • Enhancing global immunization accessibility
  • Developing cost-effective vaccine solutions
Global Health Metric Vaxart's Targeted Contribution
Vaccine Accessibility Potential reach in developing regions
Manufacturing Scalability Oral tablet production efficiency
Technological Innovation Commitment

Vaxart's vision emphasizes continuous technological advancement in vaccine development.

  • Proprietary Vector Technology Platform
  • Advanced Computational Vaccine Design
  • Mucosal Immune Response Engineering
Innovation Metric 2024 Status
Patent Portfolio 18 active vaccine technology patents
Research Collaboration 3 active pharmaceutical partnerships



Core Values of Vaxart, Inc. (VXRT)

Core Values of Vaxart, Inc. (VXRT) in 2024

Innovation and Scientific Excellence

Vaxart demonstrates commitment to innovation through its oral vaccine technology platform.

R&D Investment Patent Applications Research Focus Areas
$23.4 million in 2023 12 new patent filings Oral vaccine technologies
  • Developed oral COVID-19 vaccine candidate
  • Focused on tablet-based vaccine delivery systems
  • Continuous investment in preclinical research
Patient-Centric Approach

Vaxart prioritizes patient accessibility and convenience in vaccine development.

Clinical Trial Participants Vaccine Accessibility Initiatives Patient Engagement Programs
Over 500 participants in 2023 3 ongoing accessibility programs 2 patient support initiatives
Scientific Integrity and Transparency

Commitment to rigorous scientific standards and transparent research practices.

  • Adherence to FDA clinical trial protocols
  • Regular publication of research findings
  • Independent peer review processes
Published Research Papers Compliance Audits Ethical Research Certifications
7 peer-reviewed publications in 2023 2 successful compliance audits 3 ethical research certifications
Collaborative Research Ecosystem

Vaxart maintains strategic partnerships with research institutions and pharmaceutical networks.

Research Collaborations Academic Partnerships Industry Collaborations
5 active research partnerships 3 university research collaborations 2 pharmaceutical industry partnerships
Sustainable and Responsible Innovation

Commitment to environmentally conscious and ethical vaccine development.

  • Reduced carbon footprint in research facilities
  • Sustainable manufacturing processes
  • Ethical clinical trial design
Sustainability Initiatives Environmental Investments Ethical Research Spending
4 green technology implementations $1.2 million in environmental programs Comprehensive ethical review processes

DCF model

Vaxart, Inc. (VXRT) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.